Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.Peer-Reviewed Original ResearchConceptsClinical trialsHNSCC cellsMatrix metalloproteinasesHuman papillomavirus-associated headNeck squamous cell carcinomaSquamous cell carcinomaAbility of HPVClin Cancer ResTumor cell proliferationNeck cancer cellsWindow trialsCell carcinomaEffective therapyPreclinical modelsHPVHPV oncogenesMouse modelMouse blood vesselsDNA demethylating agentHNSCCXenografted tumorsHPV genesIFN responseTherapyTumor samplesIDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
Wirth L, Burtness B, Mehra R, Bauman J, Lee J, Smith N, Lefranc-Torres A, Westra W, Bishop J, Faquin W, Lin D, Pai S. IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC. Journal Of Clinical Oncology 2017, 35: 6053-6053. DOI: 10.1200/jco.2017.35.15_suppl.6053.Peer-Reviewed Original ResearchHPV- HNSCCsPD-L1Clinical responseHNSCC patientsResponse rateAnti-PD-1 monotherapyAnti-PD-1 therapyHuman papillomavirus-associated headAnti-PD-1 blockadeNeck squamous cell carcinomaAdaptive immune resistanceAnti-PD1 monotherapyHPV(-) HNSCC patientsImmunogenic viral antigensImmune checkpoint moleculesPost-treatment biopsiesT cell activityImmune checkpoint pathwaysSquamous cell carcinomaQuantitative PCRImproved response ratesImmune-related genesCheckpoint moleculesPD-1IDO1 expression